Biocartis Receives EUR 1.4m Grant to Support Development of New Idylla™ Technology to Unlock Potential in Molecular Surveillance
Non-regulated information
Biocartis Announces New Collaboration with AstraZeneca to Expand Availability of Idylla™ EGFR Biomarker Testing Among Patients with Lung Cancer
Non-regulated information
Biocartis and SkylineDx Sign Collaboration to Develop the Merlin Assay, a Test Predicting Risk for Nodal Metastasis in Melanoma, on Idylla™
Inside information
Regulated information
Biocartis Launches Idylla™ GeneFusion Assay as Rapid Lab Workflow Solution for Gene Fusion Testing
Non-regulated information
New US Studies Demonstrate Idylla™ Allows Rapid First Assessment of Most Common EGFR Mutations Preceding NGS
Non-regulated information
Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods
Non-regulated information
Biocartis Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting
Non-regulated information
Biocartis Announces CE-marking of its Fully Automated Idylla™ SARS-CoV-2 Test